Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

Advertisement

Related Content

Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute
Medivation Battles UCLA Over Rights To Prostate Cancer Compound
MedImmune’s Alzheimer’s Antibody Partnership With Axerion Showcases Virtual Neuroscience R&D Operation
Pharma At Barclays, In Brief
Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” says Lechleiter At JP Morgan
Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time
Almost All Hopes Dashed For Pfizer/Medivation's Dimebon
Medivation, Orexigen Highlight Late-Stage Strategies for Closely-Watched Drugs
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
Pfizer Finds Backup For Aricept In Medivation’s Dimebon

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel